Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
The Lancet. Haematology
|
March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial
Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Journal for Immunotherapy of Cancer
|
July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
Martin Wermke, Tobias A W Holderried, Jason John Luke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
Petros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Clinical & Experimental Metastasis
|
July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)
Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
The Lancet. Oncology
|
August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Yi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Nature Medicine
|
April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Leukemia
|
June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P Steensma, Martin Wermke, Virginia M Klimek, et al.
NPJ Precision Oncology
|
June 29, 2026
Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis
Marie-Elisabeth Leßmann, Felix Carl Saalfeld, Lea Ruge, et al.
International Journal of Molecular Sciences
|
April 13, 2024
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, et al.
JAMA Oncology
|
July 9, 2026
Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320)
Farastuk Bozorgmehr, Inn Chung, Rouven Behnisch, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
The Lancet. Haematology
|
March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial
Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Journal for Immunotherapy of Cancer
|
July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
Martin Wermke, Tobias A W Holderried, Jason John Luke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
Petros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Clinical & Experimental Metastasis
|
July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)
Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
The Lancet. Oncology
|
August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Yi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Nature Medicine
|
April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Leukemia
|
June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P Steensma, Martin Wermke, Virginia M Klimek, et al.
NPJ Precision Oncology
|
June 29, 2026
Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis
Marie-Elisabeth Leßmann, Felix Carl Saalfeld, Lea Ruge, et al.
International Journal of Molecular Sciences
|
April 13, 2024
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, et al.
JAMA Oncology
|
July 9, 2026
Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320)
Farastuk Bozorgmehr, Inn Chung, Rouven Behnisch, et al.
Page
of 9